Evidence map›Paper›PMID 26908440›Full record

ArticleOncotarget2016

Genetic mutations associated with metastatic clear cell renal cell carcinoma.

Zhongjun Li, Ping Hao, Qingjian Wu, Fengjie Li, Jiang Zhao, Kaijin Wu, Cunye Qu, Yibu Chen, Meng Li, Xuelian Chen and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Zhongjun LiDepartment of Blood Transfusion, Second Affiliated Hospital, Third Military Medical University, Chongqing, P. R. China.
Ping HaoDepartment of Oncology, Second Affiliated Hospital, Third Military Medical University, Chongqing, P. R. China.
Qingjian WuDepartment of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, P. R. China.
Fengjie LiDepartment of Blood Transfusion, Second Affiliated Hospital, Third Military Medical University, Chongqing, P. R. China.
Jiang ZhaoDepartment of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, P. R. China.
Kaijin WuOstrow School of Dentistry and Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles, CA, USA.
Cunye QuOstrow School of Dentistry and Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yibu ChenBioinformatics Service, Norris Medical Library, University of Southern California, Los Angeles, CA, USA.
Meng LiBioinformatics Service, Norris Medical Library, University of Southern California, Los Angeles, CA, USA.
Xuelian ChenOstrow School of Dentistry and Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles, CA, USA.
Andres StuckyOstrow School of Dentistry and Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jiangjian ZhongZ-Genetic Medicine LLC, Temple City, CA, USA.
Longkun LiDepartment of Urology, Second Affiliated Hospital, Third Military Medical University, Chongqing, P. R. China.
Jiang F ZhongOstrow School of Dentistry and Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles, CA, USA.
University of Southern California · USArmy Medical University · CNXinqiao Hospital · CN

Funding

Multi-phase Microfluidic Devices for Characterization of Circulating Tumor CellsR01CA164509 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHONG, JOHN · 2012 to 2016
$2.0M
NCI NIH HHS R01 CA164509
6 · The paper itself

Abstract

Metastasis is the major cause of death among cancer patients, yet early detection and intervention of metastasis could significantly improve their clinical outcomes. We have sequenced and analyzed RNA (Expression) and DNA (Mutations) from the primary tumor (PT), tumor extension (TE) and lymphatic metastatic (LM) sites of patients with clear cell renal cell carcinoma (CCRCC) before treatment. Here, we report a three-nucleotide deletion near the C-region of Plk5 that is specifically associated with the lymphatic metastasis. This mutation is un-detectable in the PT, becomes detectable in the TE and dominates the LM tissue. So while only a few primary cancer cells carry this mutation, the majority of metastatic cells have this mutation. The increasing frequency of this mutation in metastatic tissue suggests that this Plk5 deletion could be used as an early indicator of CCRCC metastasis, and be identified by low cost PCR assay. A large scale clinical trial could reveal whether a simple PCR assay for this mutation at the time of nephrectomy could identify and stratify high-risk CCRCC patients for treatments.

Indexed as

Carcinoma, Renal CellDNA Mutational AnalysisHigh-Throughput Nucleotide SequencingHumansKidney NeoplasmsLymphatic MetastasisMutationProtein Serine-Threonine Kinasespolo-like kinase 5, humanProtein Serine-Threonine Kinasesmetastasis-specific mutationPlk5renal cell carcinoma

Identifiers

PMID26908440
PMCPMC4941305
OpenAlexW2296040948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.